Patents Assigned to Medical & Biological Laboratories, Co., Ltd.
-
Patent number: 7547528Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.Type: GrantFiled: January 18, 2008Date of Patent: June 16, 2009Assignees: Riken, Medical & Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Ryoko Ando, Satoshi Karasawa, Hideaki Mizuno
-
Publication number: 20090142363Abstract: The successful identification of epitope peptides specific to adenovirus belonging to subgroup B and epitope peptides exhibiting specificity to all adenoviruses using hexon proteins which exhibit the highest homology among genes of adenoviruses of various subgroups is herein described. The peptides have a function capable of efficiently inducing adenovirus-specific cytotoxic T cells (CTLs). Thus, the peptides disclosed herein find utility as vaccines for active immunization. Furthermore, CTLs induced by such peptides find utility as passive immunotherapeutic agents.Type: ApplicationFiled: August 3, 2006Publication date: June 4, 2009Applicant: MEDICAL AND BIOLOGICAL LABORATORIES, CO., LTD.Inventors: Shingo Toji, Yool-Ja Kim, Susumu Suzuki
-
Patent number: 7541451Abstract: An object of the present invention is to provide a novel fluorescent protein derived from organisms other than Aequorea victoria. According to the present invention, there is provided a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 455 nm, and the fluorescence maximum wavelength is 488 nm; (2) the molar absorption coefficient at 455 nm is 38700 or 27700; (3) the quantum yield is 0.85 or 0.81; and (4) the pH sensitivity of the fluorescent property is stable at pH 5 to 9; and a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 548 nm, and the fluorescence maximum wavelength is 561 nm; (2) the molar absorption coefficient at 548 nm is 75900 or 51000; (3) the quantum yield is 0.44 or 0.50; and (4) the pH sensitivity of the fluorescent property is pKa<5.0.Type: GrantFiled: April 24, 2007Date of Patent: June 2, 2009Assignees: RIKEN, Medical & Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Satoshi Karasawa
-
Publication number: 20090110682Abstract: Disclosed is an antibody having a high inhibitor effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.Type: ApplicationFiled: June 19, 2006Publication date: April 30, 2009Applicants: Medical & Biological Laboratories Co., Ltd., The President of National Center for Geriatrics and Gerontology, Katsuhiko Yanagisawa c/o National Center for Geriatrics and GerontologyInventors: Katsuhiko Yanagisawa, Masao Shibata
-
Patent number: 7504491Abstract: An object of the present invention is to provide a chromoprotein derived from Cnidopus japonicus. The present invention provides a chromoprotein derived from Cnidopus japonicus having the following properties: (1) the absorption maximum wavelength is 610 nm, and fluorescence is not emitted; (2) the molar absorption coefficient is 66,700 at 610 nm; and (3) the pH sensitivity of light-absorbing property is stable at between pH 4 and pH 10.Type: GrantFiled: June 10, 2003Date of Patent: March 17, 2009Assignees: Riken, Medical and Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Satoshi Karasawa
-
Publication number: 20080248011Abstract: The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be prepared based on the present invention are useful in cell immunotherapy.Type: ApplicationFiled: January 25, 2005Publication date: October 9, 2008Applicant: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD.Inventors: Tomoko Nakagawa, Shunsuke Kurei, Shingo Toji, Ayako Okabe, Motoki Kuhara, Yoshiro Kishi, Ichiro Yahara
-
Publication number: 20080227097Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.Type: ApplicationFiled: January 18, 2008Publication date: September 18, 2008Applicants: RIKEN, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.Inventors: Atsushi MIYAWAKI, Ryoko Ando, Satoshi Karasawa, Hideaki Mizuno
-
Publication number: 20080194020Abstract: The present inventors worked on elucidating the mechanism of antigen cross-presentation by dendritic cells, and revealed that foreign antigens taken up in dendritic cells are degraded by proteasomes after undergoing polyubiquitination. Based on the novel finding that polyubiquitination is involved in cross-presentation, the promotion of polyubiquitination was attempted by a number of methods, and the promotion of antigen presentation was confirmed. These methods enable the production of dendritic cells effective for inducing CTL activation.Type: ApplicationFiled: September 2, 2005Publication date: August 14, 2008Applicants: Medical and Biological Laboratories Co., Ltd., Keio UniversityInventors: Jun Imai, Mikako Maruya, Shigeo Koyasu, Hironori Hasegawa, Ichiro Yahara
-
Publication number: 20080166799Abstract: An object of the present invention is to provide a novel fluorescent protein derived from organisms other than Aequorea victoria. According to the present invention, there is provided a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 455 nm, and the fluorescence maximum wavelength is 488 nm; (2) the molar absorption coefficient at 455 nm is 38700 or 27700; (3) the quantum yield is 0.85 or 0.81; and (4) the pH sensitivity of the fluorescent property is stable at pH 5 to 9; and a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 548 nm, and the fluorescence maximum wavelength is 561 nm; (2) the molar absorption coefficient at 548 nm is 75900 or 51000; (3) the quantum yield is 0.44 or 0.50; and (4) the pH sensitivity of the fluorescent property is pKa<5.0.Type: ApplicationFiled: April 24, 2007Publication date: July 10, 2008Applicants: RIKEN, MEDICAL & BIOLOGICAL LABORATORIES CO. LTD.Inventors: Atsushi MIYAWAKI, Satoshi KARASAWA
-
Patent number: 7375201Abstract: An object of the present invention is to provide a fluorescent protein derived from organisms other than Aequorea victoria and having a novel primary structure. According to the present invention, there is provided a fluorescent protein derived from Halcurias sp. L, which has the following properties: (1) the excitation maximum wavelength is 494 nm, and the fluorescence maximum wavelength is 506 nm; (2) the molar absorption coefficient at 494 nm is 94600 M?1 cm?1; (3) the quantum yield is 0.65; and (4) the pH sensitivity of the fluorescent property is low in the range between pH 4 and pH 11.Type: GrantFiled: February 25, 2003Date of Patent: May 20, 2008Assignees: Riken, Medical & Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Ryoko Ando, Hidetomo Tanase, Satoshi Karasawa
-
Patent number: 7345157Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.Type: GrantFiled: August 22, 2003Date of Patent: March 18, 2008Assignees: Riken, Medical & Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Ryoko Ando, Satoshi Karasawa, Hideaki Mizuno
-
Patent number: 7339035Abstract: It is intended to provide an antibody efficacious in diagnosing, preventing or treating Alzheimer's disease, DNA encoding the antibody, a method of screening a drug and drugs. The amino acid sequence and the gene sequence of the variable region of an antibody, which specifically recognizes a GM1 ganglioside-bound amyloid ?-protein occurring in the early stage of ?-amyloid fibril formation, are determined. Based on the data of the amino acid sequence and the gene sequence thus obtained, an antibody is designed.Type: GrantFiled: February 2, 2004Date of Patent: March 4, 2008Assignees: Medical & Biological Laboratories Co., Ltd., Japan as Represented by the Director of Chubu National HospitalInventors: Katsuhiko Yanagisawa, Masao Shibata
-
Publication number: 20070280950Abstract: A search was conducted for functional antibodies that endogenously regulate cytokines, focusing on the relationship between inflammatory diseases and cytokines. Mice were immunized with a human peripheral blood monocyte fraction and the obtained antibodies were examined for a cytokine-regulating effect. As a result, of these antibodies, antibody #33 was confirmed to inhibit the production of numerous typical inflammatory cytokines. When, at the same time, the promoting effect of antibody #33 on IL-10 production was examined, it was revealed that antibody #33 has an effect of accelerating IL-10 production but no activity to induce an excessive IL-10 production. The antigen of this promising antibody was verified to be CD61. Therefore, it is conceivable that when anti-CD61 antibodies are applied to the treatment of inflammatory diseases, they would become pharmaceuticals with both a definite efficacy and a high safety.Type: ApplicationFiled: January 19, 2005Publication date: December 6, 2007Applicant: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD.Inventors: Ayako Okabe, Shingo Toji, Yoshiro Kishi, Ichiro Yahara
-
Patent number: 7276375Abstract: A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4,5-triphosphate (PIP3) but does not cross-react with structurally similar phospholipid antigens is advantageous for PIP3-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.Type: GrantFiled: September 30, 2004Date of Patent: October 2, 2007Assignees: Medical & Biological Laboratories Co., Ltd.Inventors: Yasuhisa Fukui, Satoshi Nagata, Ryuichi Shirai
-
Patent number: 7247449Abstract: An object of the present invention is to provide a novel fluorescent protein derived from organisms other than Aequorea victoria. According to the present invention, there is provided a fluorescent protein derived from Galaxea fascicularis, which has the following properties: (1) the molecular weight is approximately 27,000; (2) a tetramer is formed in an equilibration state; (3) the excitation maximum wavelength is 492 nm, and the fluorescence maximum wavelength is 505 nm; (4) the molar absorption coefficient is 74,100; (5) the quantum yield is 0.625; and (6) the pH sensitivity of the fluorescent property is low in the range between pH 5 and pH 12.Type: GrantFiled: October 10, 2002Date of Patent: July 24, 2007Assignees: RIKEN, Medical & Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Satoshi Karasawa, Toshio Araki
-
Patent number: 7226993Abstract: An object of the present invention is to provide a novel fluorescent protein derived from organisms other than Aequorea victoria. According to the present invention, there is provided a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 455 nm, and the fluorescence maximum wavelength is 488 nm; (2) the molar absorption coefficient at 455 nm is 38700 or 27700; (3) the quantum yield is 0.85 or 0.81; and (4) the pH sensitivity of the fluorescent property is stable at pH 5 to 9; and a fluorescent protein derived from Fungia sp., which has the following properties: (1) the excitation maximum wavelength is 548 nm, and the fluorescence maximum wavelength is 561 nm; (2) the molar absorption coefficient at 548 nm is 75900 or 51000; (3) the quantum yield is 0.44 or 0.50; and (4) the pH sensitivity of the fluorescent property is pKa<5.0.Type: GrantFiled: December 20, 2002Date of Patent: June 5, 2007Assignees: Riken, Medical & Biological Laboratories Co. Ltd.Inventors: Atsushi Miyawaki, Satoshi Karasawa
-
Publication number: 20070031912Abstract: An object of the present invention is to provide a method for analyzing the protein interaction, wherein the information about time can be obtained and the movement of protein can be monitored. The present invention provides a method for analyzing interaction between a first test protein and a second test protein which comprises the steps of: splitting a fluorescent protein capable of emitting different color of fluorescence according to passage of time into an N-terminal fragment and a C-terminal fragment; allowing the first test protein to interact with the second test protein by making coexist a fusion protein of the N-terminal fragment with the first test protein and another fusion protein of the C-terminal fragment with the second test protein; and detecting the change in the fluorescent light due to the interaction.Type: ApplicationFiled: March 28, 2006Publication date: February 8, 2007Applicants: RIKEN, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.Inventors: Atsushi Miyawaki, Satoshi Karasawa
-
Patent number: 7157286Abstract: RCAS1 in a specimen is measured by a immunologically method consisting of a step of reacting a specimen with a first anti-RCAS1 antibody capable of specifically binding to RCAS1, a step of labeling the first reaction product produced by the aforementioned step, and a step of measuring a labeled amount of the labeled first reaction product. As RCAS1, recombinant RCAS1 is used. In addition, as a first anti-RCAS1, a monoclonal antibody derived from the SiSo cell line is used.Type: GrantFiled: May 24, 2002Date of Patent: January 2, 2007Assignee: Medical & Biological Laboratories Co., Ltd.Inventors: Takeshi Watanabe, Manabu Nakashima, Kenzo Sonoda
-
Patent number: 7087396Abstract: A method for determining a soluble human ST2 in a sample conveniently at a high sensitivity and an assay kit are provided. By an immunological method comprising a step for bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2, a step for labelling a first reaction product generated in the previous step by reacting said first reaction product with a second anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from the site on ST2 where said first anti-human ST2 antibody binds and which is labelled with a label, and a step for determining the amount of the label on said first reaction product which has been labelled, a soluble human ST2 in a sample is determined. In addition, a recombinant ST2 is employed as a standard to prepare a calibration curve, based on which the ST2 in a sample is quantified.Type: GrantFiled: September 16, 2002Date of Patent: August 8, 2006Assignees: Medical Biological Laboratories Co., Ltd.Inventors: Shin-ichi Tominaga, Takao Arai, Kenji Kuroiwa, Katsuhisa Oshikawa
-
Publication number: 20060160990Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.Type: ApplicationFiled: August 22, 2003Publication date: July 20, 2006Applicants: Riken, Medical & Biological Laboratories Co., Ltd.Inventors: Atsushi Miyawaki, Ryoko Ando, Satoshi Karasawa, Hideaki Mizuno